Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
暂无分享,去创建一个
F M Muggia | G. Sutton | R. Alvarez | M. Brady | F. Muggia | P. Braly | P S Braly | M F Brady | G Sutton | T H Niemann | S L Lentz | R D Alvarez | P R Kucera | J M Small | T. Niemann | J. Small | P. Kucera | S. Lentz | R. Alvarez | Samuel L. Lentz
[1] K R Hess,et al. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. , 1994, Statistics in medicine.
[2] G. Rustin,et al. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Thigpen,et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Yordan,et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Ettinger,et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .
[6] F. Parazzini,et al. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.
[8] Gruppo Interegionale,et al. RANDOMISED COMPARISON OF CISPLATIN WITH CYCLOPHOSPHAMIDE/CISPLATIN AND WITH CYCLOPHOSPHAMIDE/DOXORUBICIN/ CISPLATIN IN ADVANCED OVARIAN CANCER , 1987, The Lancet.
[9] A. Dembo. Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[11] D. Cruickshank,et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R W Makuch,et al. Sample size requirements for comparing time-to-failure among k treatment groups. , 1982, Journal of chronic diseases.
[13] A. Gadducci,et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Berek,et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Yordan,et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.
[16] W. J. Conover,et al. Practical Nonparametric Statistics , 1972 .
[17] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[18] M. Gore,et al. A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group. , 1993, British Journal of Cancer.